The development of drug-eluting stents (DES) has improved the invasive treatment of obstructive coronary artery disease by reducing both, restenosis rate and need for reinterventions. This success resulted in a widespread utilization of DES in clinical practice and entailed many clinical research programs. In addition, numerous laboratory examinations of DES have been performed. The majority of this in vitro and pre-clinical research was performed by the DES-developing companies. Only occasionally such data are fully accessible for the public.
|Award date||11 Oct 2013|
|Place of Publication||Enschede|
|Publication status||Published - 11 Oct 2013|